nodes	percent_of_prediction	percent_of_DWPC	metapath
Temozolomide—Alkylating Activity—Dacarbazine—muscle cancer	0.918	1	CiPCiCtD
Temozolomide—Abdominal pain—Dactinomycin—muscle cancer	0.000105	0.00129	CcSEcCtD
Temozolomide—Body temperature increased—Dactinomycin—muscle cancer	0.000105	0.00129	CcSEcCtD
Temozolomide—Decreased appetite—Vincristine—muscle cancer	0.000103	0.00126	CcSEcCtD
Temozolomide—Cough—Etoposide—muscle cancer	0.000103	0.00126	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Vincristine—muscle cancer	0.000102	0.00126	CcSEcCtD
Temozolomide—Fatigue—Vincristine—muscle cancer	0.000102	0.00125	CcSEcCtD
Temozolomide—Convulsion—Etoposide—muscle cancer	0.000102	0.00125	CcSEcCtD
Temozolomide—Hypertension—Etoposide—muscle cancer	0.000102	0.00125	CcSEcCtD
Temozolomide—Constipation—Vincristine—muscle cancer	0.000101	0.00124	CcSEcCtD
Temozolomide—Pain—Vincristine—muscle cancer	0.000101	0.00124	CcSEcCtD
Temozolomide—Diplopia—Doxorubicin—muscle cancer	0.000101	0.00124	CcSEcCtD
Temozolomide—Affect lability—Doxorubicin—muscle cancer	9.98e-05	0.00122	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	9.95e-05	0.00122	CcSEcCtD
Temozolomide—Discomfort—Etoposide—muscle cancer	9.9e-05	0.00121	CcSEcCtD
Temozolomide—Face oedema—Doxorubicin—muscle cancer	9.79e-05	0.0012	CcSEcCtD
Temozolomide—Hypersensitivity—Dactinomycin—muscle cancer	9.78e-05	0.0012	CcSEcCtD
Temozolomide—Gastrointestinal pain—Vincristine—muscle cancer	9.7e-05	0.00119	CcSEcCtD
Temozolomide—Confusional state—Etoposide—muscle cancer	9.68e-05	0.00119	CcSEcCtD
Temozolomide—Pancytopenia—Methotrexate—muscle cancer	9.61e-05	0.00118	CcSEcCtD
Temozolomide—Anaphylactic shock—Etoposide—muscle cancer	9.61e-05	0.00118	CcSEcCtD
Temozolomide—Mood swings—Doxorubicin—muscle cancer	9.6e-05	0.00118	CcSEcCtD
Temozolomide—Infection—Etoposide—muscle cancer	9.54e-05	0.00117	CcSEcCtD
Temozolomide—Ataxia—Doxorubicin—muscle cancer	9.53e-05	0.00117	CcSEcCtD
Temozolomide—Asthenia—Dactinomycin—muscle cancer	9.52e-05	0.00117	CcSEcCtD
Temozolomide—Dysuria—Methotrexate—muscle cancer	9.46e-05	0.00116	CcSEcCtD
Temozolomide—Neutropenia—Methotrexate—muscle cancer	9.46e-05	0.00116	CcSEcCtD
Temozolomide—Dehydration—Doxorubicin—muscle cancer	9.43e-05	0.00116	CcSEcCtD
Temozolomide—Thrombocytopenia—Etoposide—muscle cancer	9.4e-05	0.00115	CcSEcCtD
Temozolomide—Upper respiratory tract infection—Methotrexate—muscle cancer	9.4e-05	0.00115	CcSEcCtD
Temozolomide—Abdominal pain—Vincristine—muscle cancer	9.37e-05	0.00115	CcSEcCtD
Temozolomide—Body temperature increased—Vincristine—muscle cancer	9.37e-05	0.00115	CcSEcCtD
Temozolomide—Skin disorder—Etoposide—muscle cancer	9.33e-05	0.00114	CcSEcCtD
Temozolomide—Erectile dysfunction—Methotrexate—muscle cancer	9.32e-05	0.00114	CcSEcCtD
Temozolomide—Dry skin—Doxorubicin—muscle cancer	9.29e-05	0.00114	CcSEcCtD
Temozolomide—Hyperhidrosis—Etoposide—muscle cancer	9.29e-05	0.00114	CcSEcCtD
Temozolomide—Photosensitivity reaction—Methotrexate—muscle cancer	9.23e-05	0.00113	CcSEcCtD
Temozolomide—Hypokalaemia—Doxorubicin—muscle cancer	9.22e-05	0.00113	CcSEcCtD
Temozolomide—Breast disorder—Doxorubicin—muscle cancer	9.16e-05	0.00112	CcSEcCtD
Temozolomide—Anorexia—Etoposide—muscle cancer	9.16e-05	0.00112	CcSEcCtD
Temozolomide—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	9.13e-05	0.00112	CcSEcCtD
Temozolomide—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	9.13e-05	0.00112	CcSEcCtD
Temozolomide—Diarrhoea—Dactinomycin—muscle cancer	9.08e-05	0.00111	CcSEcCtD
Temozolomide—Pneumonia—Methotrexate—muscle cancer	9.07e-05	0.00111	CcSEcCtD
Temozolomide—Infestation—Methotrexate—muscle cancer	9.02e-05	0.00111	CcSEcCtD
Temozolomide—Infestation NOS—Methotrexate—muscle cancer	9.02e-05	0.00111	CcSEcCtD
Temozolomide—Depression—Methotrexate—muscle cancer	8.99e-05	0.0011	CcSEcCtD
Temozolomide—Stevens-Johnson syndrome—Methotrexate—muscle cancer	8.94e-05	0.0011	CcSEcCtD
Temozolomide—Muscular weakness—Doxorubicin—muscle cancer	8.94e-05	0.0011	CcSEcCtD
Temozolomide—Alanine aminotransferase increased—Doxorubicin—muscle cancer	8.94e-05	0.0011	CcSEcCtD
Temozolomide—Abdominal distension—Doxorubicin—muscle cancer	8.82e-05	0.00108	CcSEcCtD
Temozolomide—Stomatitis—Methotrexate—muscle cancer	8.79e-05	0.00108	CcSEcCtD
Temozolomide—Dysphagia—Doxorubicin—muscle cancer	8.76e-05	0.00107	CcSEcCtD
Temozolomide—Hypersensitivity—Vincristine—muscle cancer	8.74e-05	0.00107	CcSEcCtD
Temozolomide—Paraesthesia—Etoposide—muscle cancer	8.62e-05	0.00106	CcSEcCtD
Temozolomide—Dyspnoea—Etoposide—muscle cancer	8.56e-05	0.00105	CcSEcCtD
Temozolomide—Somnolence—Etoposide—muscle cancer	8.54e-05	0.00105	CcSEcCtD
Temozolomide—Hepatobiliary disease—Methotrexate—muscle cancer	8.53e-05	0.00105	CcSEcCtD
Temozolomide—Asthenia—Vincristine—muscle cancer	8.51e-05	0.00104	CcSEcCtD
Temozolomide—Vomiting—Dactinomycin—muscle cancer	8.44e-05	0.00103	CcSEcCtD
Temozolomide—Bronchitis—Doxorubicin—muscle cancer	8.43e-05	0.00103	CcSEcCtD
Temozolomide—Rash—Dactinomycin—muscle cancer	8.37e-05	0.00103	CcSEcCtD
Temozolomide—Decreased appetite—Etoposide—muscle cancer	8.35e-05	0.00102	CcSEcCtD
Temozolomide—Pancytopenia—Doxorubicin—muscle cancer	8.32e-05	0.00102	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Etoposide—muscle cancer	8.29e-05	0.00102	CcSEcCtD
Temozolomide—Fatigue—Etoposide—muscle cancer	8.28e-05	0.00102	CcSEcCtD
Temozolomide—Pain—Etoposide—muscle cancer	8.21e-05	0.00101	CcSEcCtD
Temozolomide—Constipation—Etoposide—muscle cancer	8.21e-05	0.00101	CcSEcCtD
Temozolomide—Dysuria—Doxorubicin—muscle cancer	8.19e-05	0.001	CcSEcCtD
Temozolomide—Neutropenia—Doxorubicin—muscle cancer	8.19e-05	0.001	CcSEcCtD
Temozolomide—Upper respiratory tract infection—Doxorubicin—muscle cancer	8.14e-05	0.000999	CcSEcCtD
Temozolomide—Haemoglobin—Methotrexate—muscle cancer	8.14e-05	0.000998	CcSEcCtD
Temozolomide—Diarrhoea—Vincristine—muscle cancer	8.11e-05	0.000995	CcSEcCtD
Temozolomide—Haemorrhage—Methotrexate—muscle cancer	8.1e-05	0.000993	CcSEcCtD
Temozolomide—Hepatitis—Methotrexate—muscle cancer	8.1e-05	0.000993	CcSEcCtD
Temozolomide—Pollakiuria—Doxorubicin—muscle cancer	8.09e-05	0.000993	CcSEcCtD
Temozolomide—Pharyngitis—Methotrexate—muscle cancer	8.04e-05	0.000986	CcSEcCtD
Temozolomide—Urinary tract disorder—Methotrexate—muscle cancer	8e-05	0.000981	CcSEcCtD
Temozolomide—Photosensitivity reaction—Doxorubicin—muscle cancer	8e-05	0.000981	CcSEcCtD
Temozolomide—Weight increased—Doxorubicin—muscle cancer	7.97e-05	0.000978	CcSEcCtD
Temozolomide—Urethral disorder—Methotrexate—muscle cancer	7.94e-05	0.000974	CcSEcCtD
Temozolomide—Weight decreased—Doxorubicin—muscle cancer	7.93e-05	0.000972	CcSEcCtD
Temozolomide—Feeling abnormal—Etoposide—muscle cancer	7.92e-05	0.000971	CcSEcCtD
Temozolomide—Hyperglycaemia—Doxorubicin—muscle cancer	7.9e-05	0.000969	CcSEcCtD
Temozolomide—Nausea—Dactinomycin—muscle cancer	7.88e-05	0.000967	CcSEcCtD
Temozolomide—Pneumonia—Doxorubicin—muscle cancer	7.86e-05	0.000964	CcSEcCtD
Temozolomide—Gastrointestinal pain—Etoposide—muscle cancer	7.85e-05	0.000963	CcSEcCtD
Temozolomide—Dizziness—Vincristine—muscle cancer	7.84e-05	0.000962	CcSEcCtD
Temozolomide—Infestation—Doxorubicin—muscle cancer	7.81e-05	0.000958	CcSEcCtD
Temozolomide—Infestation NOS—Doxorubicin—muscle cancer	7.81e-05	0.000958	CcSEcCtD
Temozolomide—Visual impairment—Methotrexate—muscle cancer	7.8e-05	0.000957	CcSEcCtD
Temozolomide—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	7.74e-05	0.00095	CcSEcCtD
Temozolomide—Erythema multiforme—Methotrexate—muscle cancer	7.66e-05	0.000939	CcSEcCtD
Temozolomide—Neuropathy peripheral—Doxorubicin—muscle cancer	7.66e-05	0.000939	CcSEcCtD
Temozolomide—Urticaria—Etoposide—muscle cancer	7.63e-05	0.000936	CcSEcCtD
Temozolomide—Stomatitis—Doxorubicin—muscle cancer	7.61e-05	0.000934	CcSEcCtD
Temozolomide—Abdominal pain—Etoposide—muscle cancer	7.59e-05	0.000931	CcSEcCtD
Temozolomide—Body temperature increased—Etoposide—muscle cancer	7.59e-05	0.000931	CcSEcCtD
Temozolomide—Urinary tract infection—Doxorubicin—muscle cancer	7.59e-05	0.000931	CcSEcCtD
Temozolomide—Eye disorder—Methotrexate—muscle cancer	7.57e-05	0.000928	CcSEcCtD
Temozolomide—Tinnitus—Methotrexate—muscle cancer	7.55e-05	0.000926	CcSEcCtD
Temozolomide—Vomiting—Vincristine—muscle cancer	7.54e-05	0.000925	CcSEcCtD
Temozolomide—Cardiac disorder—Methotrexate—muscle cancer	7.52e-05	0.000922	CcSEcCtD
Temozolomide—Rash—Vincristine—muscle cancer	7.48e-05	0.000917	CcSEcCtD
Temozolomide—Dermatitis—Vincristine—muscle cancer	7.47e-05	0.000916	CcSEcCtD
Temozolomide—Headache—Vincristine—muscle cancer	7.43e-05	0.000911	CcSEcCtD
Temozolomide—Hepatobiliary disease—Doxorubicin—muscle cancer	7.39e-05	0.000906	CcSEcCtD
Temozolomide—Angiopathy—Methotrexate—muscle cancer	7.35e-05	0.000901	CcSEcCtD
Temozolomide—Sinusitis—Doxorubicin—muscle cancer	7.33e-05	0.000899	CcSEcCtD
Temozolomide—Immune system disorder—Methotrexate—muscle cancer	7.31e-05	0.000897	CcSEcCtD
Temozolomide—Mediastinal disorder—Methotrexate—muscle cancer	7.3e-05	0.000895	CcSEcCtD
Temozolomide—Chills—Methotrexate—muscle cancer	7.27e-05	0.000891	CcSEcCtD
Temozolomide—Alopecia—Methotrexate—muscle cancer	7.16e-05	0.000878	CcSEcCtD
Temozolomide—Mental disorder—Methotrexate—muscle cancer	7.09e-05	0.00087	CcSEcCtD
Temozolomide—Hypersensitivity—Etoposide—muscle cancer	7.08e-05	0.000868	CcSEcCtD
Temozolomide—Erythema—Methotrexate—muscle cancer	7.05e-05	0.000865	CcSEcCtD
Temozolomide—Malnutrition—Methotrexate—muscle cancer	7.05e-05	0.000865	CcSEcCtD
Temozolomide—Haemoglobin—Doxorubicin—muscle cancer	7.05e-05	0.000864	CcSEcCtD
Temozolomide—Nausea—Vincristine—muscle cancer	7.04e-05	0.000864	CcSEcCtD
Temozolomide—Hepatitis—Doxorubicin—muscle cancer	7.01e-05	0.00086	CcSEcCtD
Temozolomide—Haemorrhage—Doxorubicin—muscle cancer	7.01e-05	0.00086	CcSEcCtD
Temozolomide—Hypoaesthesia—Doxorubicin—muscle cancer	6.98e-05	0.000856	CcSEcCtD
Temozolomide—Pharyngitis—Doxorubicin—muscle cancer	6.96e-05	0.000854	CcSEcCtD
Temozolomide—Urinary tract disorder—Doxorubicin—muscle cancer	6.92e-05	0.000849	CcSEcCtD
Temozolomide—Oedema peripheral—Doxorubicin—muscle cancer	6.91e-05	0.000847	CcSEcCtD
Temozolomide—Dysgeusia—Methotrexate—muscle cancer	6.9e-05	0.000847	CcSEcCtD
Temozolomide—Asthenia—Etoposide—muscle cancer	6.89e-05	0.000845	CcSEcCtD
Temozolomide—Connective tissue disorder—Doxorubicin—muscle cancer	6.89e-05	0.000845	CcSEcCtD
Temozolomide—Urethral disorder—Doxorubicin—muscle cancer	6.87e-05	0.000843	CcSEcCtD
Temozolomide—Back pain—Methotrexate—muscle cancer	6.82e-05	0.000836	CcSEcCtD
Temozolomide—Pruritus—Etoposide—muscle cancer	6.8e-05	0.000833	CcSEcCtD
Temozolomide—Visual impairment—Doxorubicin—muscle cancer	6.76e-05	0.000829	CcSEcCtD
Temozolomide—Vision blurred—Methotrexate—muscle cancer	6.64e-05	0.000815	CcSEcCtD
Temozolomide—Erythema multiforme—Doxorubicin—muscle cancer	6.63e-05	0.000813	CcSEcCtD
Temozolomide—Diarrhoea—Etoposide—muscle cancer	6.57e-05	0.000806	CcSEcCtD
Temozolomide—Eye disorder—Doxorubicin—muscle cancer	6.55e-05	0.000804	CcSEcCtD
Temozolomide—Ill-defined disorder—Methotrexate—muscle cancer	6.54e-05	0.000802	CcSEcCtD
Temozolomide—Tinnitus—Doxorubicin—muscle cancer	6.54e-05	0.000802	CcSEcCtD
Temozolomide—Anaemia—Methotrexate—muscle cancer	6.52e-05	0.000799	CcSEcCtD
Temozolomide—Flushing—Doxorubicin—muscle cancer	6.51e-05	0.000798	CcSEcCtD
Temozolomide—Cardiac disorder—Doxorubicin—muscle cancer	6.51e-05	0.000798	CcSEcCtD
Temozolomide—Angiopathy—Doxorubicin—muscle cancer	6.36e-05	0.00078	CcSEcCtD
Temozolomide—Malaise—Methotrexate—muscle cancer	6.36e-05	0.00078	CcSEcCtD
Temozolomide—Dizziness—Etoposide—muscle cancer	6.35e-05	0.000779	CcSEcCtD
Temozolomide—Immune system disorder—Doxorubicin—muscle cancer	6.33e-05	0.000777	CcSEcCtD
Temozolomide—Vertigo—Methotrexate—muscle cancer	6.33e-05	0.000777	CcSEcCtD
Temozolomide—Mediastinal disorder—Doxorubicin—muscle cancer	6.32e-05	0.000775	CcSEcCtD
Temozolomide—Leukopenia—Methotrexate—muscle cancer	6.31e-05	0.000774	CcSEcCtD
Temozolomide—Chills—Doxorubicin—muscle cancer	6.29e-05	0.000772	CcSEcCtD
Temozolomide—Alopecia—Doxorubicin—muscle cancer	6.2e-05	0.00076	CcSEcCtD
Temozolomide—Cough—Methotrexate—muscle cancer	6.15e-05	0.000754	CcSEcCtD
Temozolomide—Mental disorder—Doxorubicin—muscle cancer	6.14e-05	0.000753	CcSEcCtD
Temozolomide—Convulsion—Methotrexate—muscle cancer	6.11e-05	0.000749	CcSEcCtD
Temozolomide—Vomiting—Etoposide—muscle cancer	6.11e-05	0.000749	CcSEcCtD
Temozolomide—Malnutrition—Doxorubicin—muscle cancer	6.1e-05	0.000749	CcSEcCtD
Temozolomide—Erythema—Doxorubicin—muscle cancer	6.1e-05	0.000749	CcSEcCtD
Temozolomide—Rash—Etoposide—muscle cancer	6.06e-05	0.000743	CcSEcCtD
Temozolomide—Dermatitis—Etoposide—muscle cancer	6.05e-05	0.000742	CcSEcCtD
Temozolomide—Headache—Etoposide—muscle cancer	6.02e-05	0.000738	CcSEcCtD
Temozolomide—Arthralgia—Methotrexate—muscle cancer	6e-05	0.000736	CcSEcCtD
Temozolomide—Myalgia—Methotrexate—muscle cancer	6e-05	0.000736	CcSEcCtD
Temozolomide—Dysgeusia—Doxorubicin—muscle cancer	5.98e-05	0.000733	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	5.96e-05	0.000731	CcSEcCtD
Temozolomide—Discomfort—Methotrexate—muscle cancer	5.93e-05	0.000727	CcSEcCtD
Temozolomide—Back pain—Doxorubicin—muscle cancer	5.9e-05	0.000724	CcSEcCtD
Temozolomide—Confusional state—Methotrexate—muscle cancer	5.8e-05	0.000711	CcSEcCtD
Temozolomide—Anaphylactic shock—Methotrexate—muscle cancer	5.75e-05	0.000706	CcSEcCtD
Temozolomide—Vision blurred—Doxorubicin—muscle cancer	5.75e-05	0.000706	CcSEcCtD
Temozolomide—Infection—Methotrexate—muscle cancer	5.72e-05	0.000701	CcSEcCtD
Temozolomide—Nausea—Etoposide—muscle cancer	5.71e-05	0.0007	CcSEcCtD
Temozolomide—Ill-defined disorder—Doxorubicin—muscle cancer	5.66e-05	0.000695	CcSEcCtD
Temozolomide—Nervous system disorder—Methotrexate—muscle cancer	5.64e-05	0.000692	CcSEcCtD
Temozolomide—Anaemia—Doxorubicin—muscle cancer	5.64e-05	0.000692	CcSEcCtD
Temozolomide—Thrombocytopenia—Methotrexate—muscle cancer	5.63e-05	0.000691	CcSEcCtD
Temozolomide—Agitation—Doxorubicin—muscle cancer	5.61e-05	0.000688	CcSEcCtD
Temozolomide—Skin disorder—Methotrexate—muscle cancer	5.59e-05	0.000685	CcSEcCtD
Temozolomide—Hyperhidrosis—Methotrexate—muscle cancer	5.56e-05	0.000682	CcSEcCtD
Temozolomide—Malaise—Doxorubicin—muscle cancer	5.5e-05	0.000675	CcSEcCtD
Temozolomide—Vertigo—Doxorubicin—muscle cancer	5.48e-05	0.000673	CcSEcCtD
Temozolomide—Anorexia—Methotrexate—muscle cancer	5.48e-05	0.000673	CcSEcCtD
Temozolomide—Leukopenia—Doxorubicin—muscle cancer	5.46e-05	0.00067	CcSEcCtD
Temozolomide—Palpitations—Doxorubicin—muscle cancer	5.39e-05	0.000662	CcSEcCtD
Temozolomide—Cough—Doxorubicin—muscle cancer	5.33e-05	0.000653	CcSEcCtD
Temozolomide—Convulsion—Doxorubicin—muscle cancer	5.29e-05	0.000649	CcSEcCtD
Temozolomide—Hypertension—Doxorubicin—muscle cancer	5.27e-05	0.000646	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Methotrexate—muscle cancer	5.24e-05	0.000643	CcSEcCtD
Temozolomide—Insomnia—Methotrexate—muscle cancer	5.2e-05	0.000638	CcSEcCtD
Temozolomide—Arthralgia—Doxorubicin—muscle cancer	5.2e-05	0.000637	CcSEcCtD
Temozolomide—Myalgia—Doxorubicin—muscle cancer	5.2e-05	0.000637	CcSEcCtD
Temozolomide—Anxiety—Doxorubicin—muscle cancer	5.18e-05	0.000635	CcSEcCtD
Temozolomide—Paraesthesia—Methotrexate—muscle cancer	5.17e-05	0.000634	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	5.16e-05	0.000633	CcSEcCtD
Temozolomide—Discomfort—Doxorubicin—muscle cancer	5.13e-05	0.00063	CcSEcCtD
Temozolomide—Dyspnoea—Methotrexate—muscle cancer	5.13e-05	0.000629	CcSEcCtD
Temozolomide—Somnolence—Methotrexate—muscle cancer	5.11e-05	0.000627	CcSEcCtD
Temozolomide—Dry mouth—Doxorubicin—muscle cancer	5.08e-05	0.000623	CcSEcCtD
Temozolomide—Dyspepsia—Methotrexate—muscle cancer	5.06e-05	0.000621	CcSEcCtD
Temozolomide—Confusional state—Doxorubicin—muscle cancer	5.02e-05	0.000616	CcSEcCtD
Temozolomide—Decreased appetite—Methotrexate—muscle cancer	5e-05	0.000613	CcSEcCtD
Temozolomide—Anaphylactic shock—Doxorubicin—muscle cancer	4.98e-05	0.000611	CcSEcCtD
Temozolomide—Oedema—Doxorubicin—muscle cancer	4.98e-05	0.000611	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Methotrexate—muscle cancer	4.97e-05	0.000609	CcSEcCtD
Temozolomide—Fatigue—Methotrexate—muscle cancer	4.96e-05	0.000608	CcSEcCtD
Temozolomide—Infection—Doxorubicin—muscle cancer	4.95e-05	0.000607	CcSEcCtD
Temozolomide—Pain—Methotrexate—muscle cancer	4.92e-05	0.000603	CcSEcCtD
Temozolomide—Nervous system disorder—Doxorubicin—muscle cancer	4.89e-05	0.000599	CcSEcCtD
Temozolomide—Thrombocytopenia—Doxorubicin—muscle cancer	4.88e-05	0.000598	CcSEcCtD
Temozolomide—Skin disorder—Doxorubicin—muscle cancer	4.84e-05	0.000593	CcSEcCtD
Temozolomide—Hyperhidrosis—Doxorubicin—muscle cancer	4.82e-05	0.000591	CcSEcCtD
Temozolomide—Anorexia—Doxorubicin—muscle cancer	4.75e-05	0.000582	CcSEcCtD
Temozolomide—Feeling abnormal—Methotrexate—muscle cancer	4.74e-05	0.000581	CcSEcCtD
Temozolomide—Gastrointestinal pain—Methotrexate—muscle cancer	4.7e-05	0.000577	CcSEcCtD
Temozolomide—Urticaria—Methotrexate—muscle cancer	4.57e-05	0.000561	CcSEcCtD
Temozolomide—Abdominal pain—Methotrexate—muscle cancer	4.55e-05	0.000558	CcSEcCtD
Temozolomide—Body temperature increased—Methotrexate—muscle cancer	4.55e-05	0.000558	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Doxorubicin—muscle cancer	4.54e-05	0.000557	CcSEcCtD
Temozolomide—Insomnia—Doxorubicin—muscle cancer	4.51e-05	0.000553	CcSEcCtD
Temozolomide—Paraesthesia—Doxorubicin—muscle cancer	4.47e-05	0.000549	CcSEcCtD
Temozolomide—Dyspnoea—Doxorubicin—muscle cancer	4.44e-05	0.000545	CcSEcCtD
Temozolomide—Somnolence—Doxorubicin—muscle cancer	4.43e-05	0.000543	CcSEcCtD
Temozolomide—Dyspepsia—Doxorubicin—muscle cancer	4.39e-05	0.000538	CcSEcCtD
Temozolomide—Decreased appetite—Doxorubicin—muscle cancer	4.33e-05	0.000531	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Doxorubicin—muscle cancer	4.3e-05	0.000527	CcSEcCtD
Temozolomide—Fatigue—Doxorubicin—muscle cancer	4.3e-05	0.000527	CcSEcCtD
Temozolomide—Constipation—Doxorubicin—muscle cancer	4.26e-05	0.000522	CcSEcCtD
Temozolomide—Pain—Doxorubicin—muscle cancer	4.26e-05	0.000522	CcSEcCtD
Temozolomide—Hypersensitivity—Methotrexate—muscle cancer	4.24e-05	0.00052	CcSEcCtD
Temozolomide—Asthenia—Methotrexate—muscle cancer	4.13e-05	0.000506	CcSEcCtD
Temozolomide—Feeling abnormal—Doxorubicin—muscle cancer	4.11e-05	0.000503	CcSEcCtD
Temozolomide—Gastrointestinal pain—Doxorubicin—muscle cancer	4.07e-05	0.0005	CcSEcCtD
Temozolomide—Pruritus—Methotrexate—muscle cancer	4.07e-05	0.000499	CcSEcCtD
Temozolomide—Urticaria—Doxorubicin—muscle cancer	3.96e-05	0.000485	CcSEcCtD
Temozolomide—Body temperature increased—Doxorubicin—muscle cancer	3.94e-05	0.000483	CcSEcCtD
Temozolomide—Abdominal pain—Doxorubicin—muscle cancer	3.94e-05	0.000483	CcSEcCtD
Temozolomide—Diarrhoea—Methotrexate—muscle cancer	3.94e-05	0.000483	CcSEcCtD
Temozolomide—Dizziness—Methotrexate—muscle cancer	3.8e-05	0.000467	CcSEcCtD
Temozolomide—Hypersensitivity—Doxorubicin—muscle cancer	3.67e-05	0.00045	CcSEcCtD
Temozolomide—Vomiting—Methotrexate—muscle cancer	3.66e-05	0.000449	CcSEcCtD
Temozolomide—Rash—Methotrexate—muscle cancer	3.63e-05	0.000445	CcSEcCtD
Temozolomide—Dermatitis—Methotrexate—muscle cancer	3.62e-05	0.000444	CcSEcCtD
Temozolomide—Headache—Methotrexate—muscle cancer	3.6e-05	0.000442	CcSEcCtD
Temozolomide—Asthenia—Doxorubicin—muscle cancer	3.57e-05	0.000438	CcSEcCtD
Temozolomide—Pruritus—Doxorubicin—muscle cancer	3.52e-05	0.000432	CcSEcCtD
Temozolomide—Nausea—Methotrexate—muscle cancer	3.42e-05	0.000419	CcSEcCtD
Temozolomide—Diarrhoea—Doxorubicin—muscle cancer	3.41e-05	0.000418	CcSEcCtD
Temozolomide—Dizziness—Doxorubicin—muscle cancer	3.29e-05	0.000404	CcSEcCtD
Temozolomide—Vomiting—Doxorubicin—muscle cancer	3.17e-05	0.000388	CcSEcCtD
Temozolomide—Rash—Doxorubicin—muscle cancer	3.14e-05	0.000385	CcSEcCtD
Temozolomide—Dermatitis—Doxorubicin—muscle cancer	3.14e-05	0.000385	CcSEcCtD
Temozolomide—Headache—Doxorubicin—muscle cancer	3.12e-05	0.000383	CcSEcCtD
Temozolomide—Nausea—Doxorubicin—muscle cancer	2.96e-05	0.000363	CcSEcCtD
